Normal Versus Dual Wave Insulin Bolus for High-protein Food
Type 1 Diabetes
About this trial
This is an interventional treatment trial for Type 1 Diabetes focused on measuring dual-wave bolus, square bolus, normal bolus, standard bolus, high-protein meal, prandial insulin requirement
Eligibility Criteria
Inclusion Criteria:
- duration of type 1 diabetes longer than 12 months
- insulin pump therapy longer than 3 months
- written informed consent by patients and parents
- patients must be willing to wear a glucose sensor for two days
- insulin requirement more than 0,5 units/kg/day
Exclusion Criteria:
- concomitant dietary restrictions (e.g. celiac disease or food allergy)
- diabetes related complications (e.g. nephropathy)
- any disease judged by the investigator to affect the trial
- withdrawal of consent to participate in the study
Sites / Locations
- Department of Pediatrics, Medical University of Warsaw, Poland
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Normal/ Dual-wave
Dual-wave/Normal
On the first study day, pre-breakfast insulin was given as a normal bolus 15 minutes before a standardized high-protein meal. On the second day, pre-breakfast insulin was given as a dual-wave bolus before the same high-protein meal. The carbo-insulin and fat-protein-insulin ratio on both study days were identical to the patient's ratio when entering trial. Kind of study bolus insulin will be a rapid-acting insulin analog same as previously used by the participant (before entering the trial) - insulin aspart, insulin lispro or insulin glulisine
On the first study day, pre-breakfast insulin was given as a dual-wave bolus 15 minutes before a standardized high-protein meal. On the second day, pre-breakfast insulin was given as a normal bolus before the same high-protein meal. The carbo-insulin and fat-protein-insulin ratio on both study days were identical to the patient's ratio when entering trial. Kind of study bolus insulin will be a rapid-acting insulin analog same as previously used by the participant (before entering the trial) - insulin aspart, insulin lispro or insulin glulisine